clinical trial · NCT07583953
An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.·early phase1·not yet recruiting·n = 50
Solid TumorsABO2109 Injection;ToripalimabABO2109 Injection;Toripalimab
brief summary
The purpose of this study is to evaluate the safety and tolerability of ABO2109 in combination with toripalimab, and to evaluate the immunogenicity, pharmacokinetics, pharmacodynamics, as well as biomarker characteristics of the investigational cancer vaccine. In addition, the antitumor activity of ABO2109 will be assessed during both dose exploration and expansion stages, the accumulative data will support the clinical development of ABO2109.
started
Apr 17, 2026
primary completion
Jan 31, 2029
completion
Apr 17, 2031
last updated
May 13, 2026
official title
An Exploratory Study of Personalized Cancer Vaccine (ABO2109) in Adjuvant Therapy of Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol